Skip to main content

Advertisement

Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)

Figure 1

Percent change in urinary GAG excretion in Korean male patients with Mucopolysaccharidosis II. After 24 weeks of treatment, the percent changes in urine GAG levels were significantly greater in idursulfase beta groups treated at dosages of 0.5 mg/kg/week and 1.0 mg/kg/week, compared to the comparator group (†P = 0.043 and ††P = 0.002, respectively). Squares represent the comparator group (N = 11), closed circles represent the idursulfase beta 0.5 mg/kg/week group (N =10), and open circles represent the idursulfase beta 1.0 mg/kg/week group (N = 10).

Back to article page